Are there variations in nivolumab administration frequency based on patient factors?

Do dosing schedules for nivolumab change with patient weight or kidney function?
Nivolumab is given as a fixed 240 mg dose every two weeks or 480 mg every four weeks regardless of body weight. No dose adjustment is required for mild-to-moderate kidney impairment, though patients with severe renal impairment are monitored more closely.

What happens when liver function is reduced?
Mild liver impairment does not alter the schedule. In moderate-to-severe hepatic impairment, clinicians often extend the interval between doses or switch to the every-four-week regimen to reduce exposure while maintaining efficacy.

Can treatment be paused or delayed for side effects?
Yes. Immune-related adverse events frequently lead to temporary holds of one to four weeks or permanent discontinuation if toxicity is severe. Resumption occurs only after symptoms resolve to grade 1 or baseline.

How do age and performance status affect frequency?
Patients over 75 or those with ECOG performance status 2 may receive the every-four-week schedule from the start to reduce clinic visits. No formal reduction in total dose is made solely on age.

Is nivolumab combined with ipilimumab given on a different timetable?
When paired with ipilimumab, nivolumab is still dosed every three weeks for four cycles, then switched to every two or four weeks as monotherapy. The combination schedule is fixed and not altered by patient factors.

When does the patent on nivolumab expire?
The composition-of-matter patent for nivolumab expires in 2028 in the United States, with additional formulation and method-of-use patents extending protection into the early 2030s. Biosimilar entry is not expected before 2028. [1]